ClinicalTrials.gg
CompletedNCT06616909Updated Oct 30, 2026Results posted

Advance Care Planning Impact on the Consistency of Older Adults With Lung Cancer and Their Potential Surrogates Regarding Life-Sustaining Treatment Preferences

An interventional study of ACP GAME and acp manual in Advanced Care Planning (ACP), ELDERLY PEOPLE and Lung Cancer (NSCLC), sponsored by National Taiwan University Hospital. Completed at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 30, 2026Now CompletedResults posted+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Lung Neoplasms by National Taiwan University Hospital — 12 open to participants now, 12 under way, 1 of them phase 3. Lung Neoplasms · National Taiwan University Hospital.

Enrollment
8th of 20
124 · median 103
Started
2024
with 1 other
No phase
16 of 46
3 open now
Registered
40th of 46
by date

Among the 46 studies in Lung Neoplasms by National Taiwan University Hospital, this one is the 8th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2024, is one of 16 with no phase, and was the 40th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

12 of the 46 studies in Lung Neoplasms by National Taiwan University Hospital are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Lung Neoplasms by National Taiwan University Hospital, or all of them as a file.
02

Study summary

This randomized controlled trial examined whether an advance care planning (ACP) tabletop game ("Walking with Wishes") could improve the consistency of life-sustaining treatment preferences between older adults with lung cancer and their potential surrogates (family members or friends), compared to a standard ACP manual. Eligible dyads (patient-surrogate pairs) were randomized 1:1 to either the tabletop game intervention or the ACP manual control group. The primary outcome was the absolute gap score on the modified Life Support Preferences Questionnaire (m-LSPQ), measuring the difference between patient and surrogate preferences for five life-sustaining treatments (antibiotics, CPR, surgery, nasogastric tube feeding, and intravenous infusion) across nine health scenarios. Secondary outcomes included state anxiety (STAI-S) for both patients and surrogates. The m-LSPQ was assessed at baseline (T0), 2 weeks (T2), and 6 weeks (T3) post-intervention. The STAI-S was additionally assessed immediately post-intervention (T1) to capture acute emotional responses to the intervention.

03

Conditions studied

  • Advanced Care Planning (ACP)
  • ELDERLY PEOPLE
  • Lung Cancer (NSCLC)
04

Who can participate

The criteria were revised on the registry on Oct 30, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. lung cancer age ≧ 60
  2. The elderly with lung cancer are conscious and have no severe visual or hearing impairment.
  3. The potential surrogate was designated by the older adult with lung cancer as the person who may make medical decisions in the future. The potential surrogate must be at least 18 years old.

Exclusion criteria

Exclusion Criteria:

  1. People with severe hearing loss and visual impairment who are unable to communicate in Mandarin and Taiwanese.
  2. The potential agent is under 18 years old
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    game ACP module

    ,Using board games as an activity intervention, a tool for discussion between elderly people with lung cancer and potential agents

    Behavioral: ACP GAME

  • Placebo comparator
    ACP Manual

    Behavioral: acp manual

Interventions

  • BehavioralACP GAME

    ,Using board games as an activity intervention, a tool for discussion between elderly people with lung cancer and potential agents

  • Behavioralacp manual

    acp manual

06

What researchers measure

Primary outcomes

  1. Absolute Gap Score on m-LSPQ Total Score Baseline

    The modified Life Support Preferences Questionnaire (m-LSPQ) contains 45 items rated from 1 (absolutely unwanted) to 5 (absolutely wanted). The total score is calculated by summing all 45 item scores and ranges from 45 to 225; higher scores indicate greater preference for receiving life-sustaining treatments. Patient and surrogate total scores are reported separately. The absolute gap score is calculated within each patient-surrogate dyad as \|surrogate total score - patient total score\|. The absolute gap score ranges from 0 to 180; smaller values indicate greater patient-surrogate concordance, with 0 indicating complete agreement.

    Time frame: Baseline (T0)

  2. Absolute Gap Score on m-LSPQ Total Score at 2 Weeks

    The modified Life Support Preferences Questionnaire (m-LSPQ) contains 45 items rated from 1 (absolutely unwanted) to 5 (absolutely wanted). The total score is calculated by summing all 45 item scores and ranges from 45 to 225; higher scores indicate a greater preference for receiving life-sustaining treatments. Patient and surrogate total scores are reported separately. For each patient-surrogate dyad, the absolute gap score is calculated as \|surrogate total score - patient total score\|. The absolute gap score ranges from 0 to 180; smaller values indicate greater patient-surrogate concordance, with 0 indicating complete agreement.

    Time frame: 2 weeks post-intervention (T2)

  3. Absolute Gap Score on m-LSPQ Total Score at 6 Weeks

    The modified Life Support Preferences Questionnaire (m-LSPQ) contains 45 items rated from 1 (absolutely unwanted) to 5 (absolutely wanted). The total score is calculated by summing all 45 item scores and ranges from 45 to 225; higher scores indicate a greater preference for receiving life-sustaining treatments. Patient and surrogate total scores are reported separately. For each patient-surrogate dyad, the absolute gap score is calculated as \|surrogate total score - patient total score\|. The absolute gap score ranges from 0 to 180; smaller values indicate greater patient-surrogate concordance, with 0 indicating complete agreement.

    Time frame: 6 weeks post-intervention (T3)

Secondary outcomes

  1. State Anxiety (STAI-S) of Patients (T0)

    The State-Trait Anxiety Inventory-State (STAI-S) assesses current state anxiety. It includes 20 items and yields a total score ranging from 20 to 80; higher scores indicate greater anxiety.

    Time frame: Baseline (T0)

  2. State Anxiety (STAI-S) of Patients (T1)

    The State-Trait Anxiety Inventory-State (STAI-S) assesses current (state) anxiety. It includes 20 items and yields a total score range of 20 to 80; higher scores indicate higher anxiety. Scores are reported as mean (standard deviation) for patients at the specified time point.

    Time frame: Immediately post-intervention (T1)

  3. State Anxiety (STAI-S) of Patients (T2)

    The State-Trait Anxiety Inventory-State (STAI-S) assesses current state anxiety. It contains 20 items and yields a total score ranging from 20 to 80; higher scores indicate greater anxiety. Scores are reported as mean and standard deviation for patients at 2 weeks post-intervention.

    Time frame: 2 weeks post-intervention (T2)

  4. State Anxiety (STAI-S) of Patients (T3)

    The State-Trait Anxiety Inventory-State (STAI-S) assesses current state anxiety. It contains 20 items and yields a total score ranging from 20 to 80; higher scores indicate greater anxiety. Scores are reported as mean and standard deviation for patients at 6 weeks post-intervention.

    Time frame: 6 weeks post-intervention (T3)

  5. State Anxiety (STAI-S ) of Surrogates (T0)

    The State-Trait Anxiety Inventory-State (STAI-S) assesses current state anxiety. It contains 20 items and yields a total score ranging from 20 to 80; higher scores indicate greater anxiety. Scores are reported as mean and standard deviation for surrogates at baseline.

    Time frame: Baseline (T0)

  6. State Anxiety (STAI-S ) of Surrogates (T1)

    The State-Trait Anxiety Inventory-State (STAI-S) assesses current state anxiety. It contains 20 items and yields a total score ranging from 20 to 80; higher scores indicate greater anxiety. Scores are reported as mean and standard deviation for surrogates immediately post-intervention.

    Time frame: immediately post-intervention (T1)

  7. State Anxiety (STAI-S ) of Surrogates (T2)

    The State-Trait Anxiety Inventory-State (STAI-S) assesses current (state) anxiety. It includes 20 items and yields a total score range of 20 to 80; higher scores indicate higher anxiety. Scores are reported as mean (standard deviation) for surrogates at the specified time point.

    Time frame: 2 weeks post-intervention (T2)

  8. State Anxiety (STAI-S ) of Surrogates (T3)

    The State-Trait Anxiety Inventory-State (STAI-S) assesses current (state) anxiety. It includes 20 items and yields a total score range of 20 to 80; higher scores indicate higher anxiety. Scores are reported as mean (standard deviation) for surrogates at the specified time point.

    Time frame: 6 weeks post-intervention (T3)

  9. Absolute Gap in Antibiotics Preference (T0)

    The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 (absolutely unwanted) to 5 (absolutely wanted). The antibiotics subscale includes 9 items, with total scores ranging from 9 to 45. Higher scores indicate a greater preference for receiving antibiotics. Patient and surrogate subscale scores are reported separately. For each patient-surrogate dyad, the absolute gap score was calculated as \|surrogate score - patient score\|. Gap scores range from 0 to 36; smaller scores indicate greater patient-surrogate concordance, with 0 indicating complete agreement.

    Time frame: Baseline (T0)

  10. Absolute Gap in Antibiotics Preference (T2)

    The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 (absolutely unwanted) to 5 (absolutely wanted). The antibiotics subscale includes 9 items, with total scores ranging from 9 to 45. Higher scores indicate a greater preference for receiving antibiotics. Patient and surrogate subscale scores are reported separately. For each patient-surrogate dyad, the absolute gap score was calculated as \|surrogate score - patient score\|. Gap scores range from 0 to 36; smaller scores indicate greater patient-surrogate concordance, with 0 indicating complete agreement.

    Time frame: 2 weeks post-intervention (T2)

  11. Absolute Gap in Antibiotics Preference (T3)

    The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 = "absolutely unwanted" to 5 = "absolutely wanted." The antibiotics subscale includes 9 items, one for each health scenario. Subscale scores are calculated by summing the 9 item scores, with possible scores ranging from 9 to 45. Higher scores indicate greater preference for receiving antibiotics as a life-sustaining treatment. The absolute gap score for antibiotics preference was calculated as \|Surrogate antibiotics subscale score - Patient antibiotics subscale score\|. Scores range from 0 to 36, with smaller values indicating greater patient-surrogate concordance.

    Time frame: 6 weeks post-intervention (T3)

  12. Absolute Gap in Cardiopulmonary Resuscitation (CPR) Preference (T0)

    The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 = "absolutely unwanted" to 5 = "absolutely wanted." The cardiopulmonary resuscitation (CPR) subscale includes 9 items, one for each health scenario. Subscale scores are calculated by summing the 9 item scores, with possible scores ranging from 9 to 45. Higher scores indicate greater preference for receiving CPR as a life-sustaining treatment. The absolute gap score was calculated as \|Surrogate CPR subscale score - Patient CPR subscale score\|. Scores range from 0 to 36, with smaller values indicating greater patient-surrogate concordance.

    Time frame: Baseline (T0)

  13. Absolute Gap in Cardiopulmonary Resuscitation (CPR) Preference (T2)

    The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 = "absolutely unwanted" to 5 = "absolutely wanted." The cardiopulmonary resuscitation (CPR) subscale includes 9 items, one for each health scenario. Subscale scores are calculated by summing the 9 item scores, with possible scores ranging from 9 to 45. Higher scores indicate greater preference for receiving CPR as a life-sustaining treatment. The absolute gap score was calculated as \|Surrogate CPR subscale score - Patient CPR subscale score\|. Scores range from 0 to 36, with smaller values indicating greater patient-surrogate concordance.

    Time frame: 2 weeks post-intervention (T2)

  14. Absolute Gap in Cardiopulmonary Resuscitation (CPR) Preference (T3)

    The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 = "absolutely unwanted" to 5 = "absolutely wanted." The cardiopulmonary resuscitation (CPR) subscale includes 9 items, one for each health scenario. Subscale scores are calculated by summing the 9 item scores, with possible scores ranging from 9 to 45. Higher scores indicate greater preference for receiving CPR as a life-sustaining treatment. The absolute gap score was calculated as \|Surrogate CPR subscale score - Patient CPR subscale score\|. Scores range from 0 to 36, with smaller values indicating greater patient-surrogate concordance.

    Time frame: 6 weeks post-intervention (T3)

  15. Absolute Gap in Surgery Preference (T0)

    The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 = "absolutely unwanted" to 5 = "absolutely wanted." The surgery subscale includes 9 items, one for each health scenario. Subscale scores are calculated by summing the 9 item scores, with possible scores ranging from 9 to 45. Higher scores indicate greater preference for receiving surgery as a life-sustaining treatment. The absolute gap score was calculated as \|Surrogate surgery subscale score - Patient surgery subscale score\|. Scores range from 0 to 36, with smaller values indicating greater patient-surrogate concordance.

    Time frame: Baseline (T0)

  16. Absolute Gap in Surgery Preference (T2)

    The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 = "absolutely unwanted" to 5 = "absolutely wanted." The surgery subscale includes 9 items, one for each health scenario. Subscale scores are calculated by summing the 9 item scores, with possible scores ranging from 9 to 45. Higher scores indicate greater preference for receiving surgery as a life-sustaining treatment. The absolute gap score was calculated as \|Surrogate surgery subscale score - Patient surgery subscale score\|. Scores range from 0 to 36, with smaller values indicating greater patient-surrogate concordance.

    Time frame: 2 weeks post-intervention (T2)

  17. Absolute Gap in Surgery Preference (T3)

    The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 = "absolutely unwanted" to 5 = "absolutely wanted." The surgery subscale includes 9 items, one for each health scenario. Subscale scores are calculated by summing the 9 item scores, with possible scores ranging from 9 to 45. Higher scores indicate greater preference for receiving surgery as a life-sustaining treatment. The absolute gap score was calculated as \|Surrogate surgery subscale score - Patient surgery subscale score\|. Scores range from 0 to 36, with smaller values indicating greater patient-surrogate concordance.

    Time frame: 6 weeks post-intervention (T3)

  18. Absolute Gap in Nasogastric Tube Feeding (NG) Preference (T0)

    The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 = "absolutely unwanted" to 5 = "absolutely wanted." The nasogastric tube feeding subscale includes 9 items, one for each health scenario. Subscale scores are calculated by summing the 9 item scores, with possible scores ranging from 9 to 45. Higher scores indicate greater preference for receiving nasogastric tube feeding as a life-sustaining treatment. The absolute gap score was calculated as \|Surrogate NG tube feeding subscale score - Patient NG tube feeding subscale score\|. Scores range from 0 to 36, with smaller values indicating greater patient-surrogate concordance.

    Time frame: Baseline (T0)

  19. Absolute Gap in Nasogastric Tube Feeding (NG) Preference (T2)

    The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 = "absolutely unwanted" to 5 = "absolutely wanted." The nasogastric tube feeding subscale includes 9 items, one for each health scenario. Subscale scores are calculated by summing the 9 item scores, with possible scores ranging from 9 to 45. Higher scores indicate greater preference for receiving nasogastric tube feeding as a life-sustaining treatment. The absolute gap score was calculated as \|Surrogate NG tube feeding subscale score - Patient NG tube feeding subscale score\|. Scores range from 0 to 36, with smaller values indicating greater patient-surrogate concordance.

    Time frame: 2 weeks post-intervention (T2)

  20. Absolute Gap in Nasogastric Tube Feeding (NG) Preference (T3)

    The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 = "absolutely unwanted" to 5 = "absolutely wanted." The nasogastric tube feeding subscale includes 9 items, one for each health scenario. Subscale scores are calculated by summing the 9 item scores, with possible scores ranging from 9 to 45. Higher scores indicate greater preference for receiving nasogastric tube feeding as a life-sustaining treatment. The absolute gap score was calculated as \|Surrogate NG tube feeding subscale score - Patient NG tube feeding subscale score\|. Scores range from 0 to 36, with smaller values indicating greater patient-surrogate concordance.

    Time frame: 6 weeks post-intervention (T3)

  21. Absolute Gap in Intravenous Infusion (IV) Preference (T0)

    The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 = "absolutely unwanted" to 5 = "absolutely wanted." The intravenous infusion subscale includes 9 items, one for each health scenario. Subscale scores are calculated by summing the 9 item scores, with possible scores ranging from 9 to 45. Higher scores indicate greater preference for receiving intravenous infusion as a life-sustaining treatment. The absolute gap score was calculated as \|Surrogate intravenous infusion subscale score - Patient intravenous infusion subscale score\|. Scores range from 0 to 36, with smaller values indicating greater patient-surrogate concordance.

    Time frame: Baseline (T0)

  22. Absolute Gap in Intravenous Infusion (IV) Preference (T2)

    The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 = "absolutely unwanted" to 5 = "absolutely wanted." The intravenous infusion subscale includes 9 items, one for each health scenario. Subscale scores are calculated by summing the 9 item scores, with possible scores ranging from 9 to 45. Higher scores indicate greater preference for receiving intravenous infusion as a life-sustaining treatment. The absolute gap score was calculated as \|Surrogate intravenous infusion subscale score - Patient intravenous infusion subscale score\|. Scores range from 0 to 36, with smaller values indicating greater patient-surrogate concordance.

    Time frame: 2 weeks post-intervention (T2)

  23. Absolute Gap in Intravenous Infusion (IV) Preference (T3)

    The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 = "absolutely unwanted" to 5 = "absolutely wanted." The intravenous infusion subscale includes 9 items, one for each health scenario. Subscale scores are calculated by summing the 9 item scores, with possible scores ranging from 9 to 45. Higher scores indicate greater preference for receiving intravenous infusion as a life-sustaining treatment. The absolute gap score was calculated as \|Surrogate intravenous infusion subscale score - Patient intravenous infusion subscale score\|. Scores range from 0 to 36, with smaller values indicating greater patient-surrogate concordance.

    Time frame: 6 weeks post-intervention (T3)

07

Results

Posted Oct 30, 2026
Limitations and caveats
The follow-up period was limited to 6 weeks, and this single-center study was conducted at one medical center in northern Taiwan, which may limit generalizability. As a dyad-based study, requiring both patients and surrogates to attend together may also have affected recruitment and participation. To clarify the assessment schedule, the m-LSPQ was assessed at T0, T2, and T3, whereas the STAI-S was assessed at T0, T1, T2, and T3 to capture immediate emotional responses after the intervention.

Participant flow

98 dyads screened; 36 declined. 62 dyads (124 individuals) randomized 1:1 to tabletop game vs ACP manual. Flow counts are individuals, not dyads.

Participant flow — Overall Study
MilestoneExperimental: ACP Tabletop GameControl: ACP Manual
Started6262
Completed5856
Not completed46
Withdrew: Withdrawal by subject40
Withdrew: Death02
Withdrew: Worsening condition04

Outcome measures

PrimaryAbsolute Gap Score on m-LSPQ Total Score Baseline

The modified Life Support Preferences Questionnaire (m-LSPQ) contains 45 items rated from 1 (absolutely unwanted) to 5 (absolutely wanted). The total score is calculated by summing all 45 item scores and ranges from 45 to 225; higher scores indicate greater preference for receiving life-sustaining treatments. Patient and surrogate total scores are reported separately. The absolute gap score is calculated within each patient-surrogate dyad as \|surrogate total score - patient total score\|. The absolute gap score ranges from 0 to 180; smaller values indicate greater patient-surrogate concordance, with 0 indicating complete agreement.

Time frame:
Baseline (T0)
Reported as:
Mean · scores on a scale
Absolute Gap Score on m-LSPQ Total Score Baseline
scores on a scaleExperimental: ACP Tabletop GameControl: ACP Manual
Patient total m-LSPQ score112.59 ± 44.69112.74 ± 40.96
Surrogate total m-LSPQ score134.17 ± 41.81136.84 ± 49.84
Absolute gap |Surrogate-Patient|48.90 ± 17.6248.77 ± 28.68
Statistical analysis
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .984 · Experimental group coefficient: 0.122 · 95% CI -11.640 to 11.885The dispersion value represents the robust (sandwich) standard error of the GEE coefficient.
SecondaryState Anxiety (STAI-S) of Patients (T0)

The State-Trait Anxiety Inventory-State (STAI-S) assesses current state anxiety. It includes 20 items and yields a total score ranging from 20 to 80; higher scores indicate greater anxiety.

Time frame:
Baseline (T0)
Reported as:
Mean · scores on a scale
State Anxiety (STAI-S) of Patients (T0)
scores on a scaleExperimental: ACP Tabletop GameControl: ACP Manual
State Anxiety (STAI-S) of Patients (T0)36.38 ± 9.2834.81 ± 11.49
Statistical analysis
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .552 · Experimental group coefficient: 1.573 · 95% CI -3.609 to 6.755The dispersion value is the robust (sandwich) standard error for the estimated GEE coefficient.
SecondaryState Anxiety (STAI-S) of Patients (T1)

The State-Trait Anxiety Inventory-State (STAI-S) assesses current (state) anxiety. It includes 20 items and yields a total score range of 20 to 80; higher scores indicate higher anxiety. Scores are reported as mean (standard deviation) for patients at the specified time point.

Time frame:
Immediately post-intervention (T1)
Reported as:
Mean · scores on a scale
State Anxiety (STAI-S) of Patients (T1)
scores on a scaleExperimental: ACP Tabletop GameControl: ACP Manual
State Anxiety (STAI-S) of Patients (T1)34.17 ± 7.4433.97 ± 8.45
Statistical analysis
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .325 · Group×time coefficient at t1: -1.368 · 95% CI -4.091 to 1.355The dispersion value is the robust (sandwich) standard error for the estimated GEE coefficient.
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .409 · Time coefficient at t1: -0.839 · 95% CI -2.828 to 1.151The dispersion value is the robust standard error for the estimated GEE coefficient.
SecondaryState Anxiety (STAI-S) of Patients (T2)

The State-Trait Anxiety Inventory-State (STAI-S) assesses current state anxiety. It contains 20 items and yields a total score ranging from 20 to 80; higher scores indicate greater anxiety. Scores are reported as mean and standard deviation for patients at 2 weeks post-intervention.

Time frame:
2 weeks post-intervention (T2)
Reported as:
Mean · scores on a scale
State Anxiety (STAI-S) of Patients (T2)
scores on a scaleExperimental: ACP Tabletop GameControl: ACP Manual
State Anxiety (STAI-S) of Patients (T2)37.00 ± 11.2336.35 ± 10.50
Statistical analysis
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .707 · Group×time coefficient at 2 weeks: -0.928 · 95% CI -5.758 to 3.903The dispersion value is the robust (sandwich) standard error for the estimated GEE coefficient.
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .253 · Time coefficient at t2: 1.548 · 95% CI -1.105 to 4.202The dispersion value is the robust standard error for the estimated GEE coefficient.
SecondaryState Anxiety (STAI-S) of Patients (T3)

The State-Trait Anxiety Inventory-State (STAI-S) assesses current state anxiety. It contains 20 items and yields a total score ranging from 20 to 80; higher scores indicate greater anxiety. Scores are reported as mean and standard deviation for patients at 6 weeks post-intervention.

Time frame:
6 weeks post-intervention (T3)
Reported as:
Mean · scores on a scale
State Anxiety (STAI-S) of Patients (T3)
scores on a scaleExperimental: ACP Tabletop GameControl: ACP Manual
State Anxiety (STAI-S) of Patients (T3)38.14 ± 10.7935.75 ± 10.57
Statistical analysis
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .923 (GEE analysis was conducted on dyad-level absolute gap scores for the m-LSPQ total score. The control group at baseline (T0) was the reference category. An AR(1) working correlation structure and robust variance estimator were used.) · Group×time coefficient at t3: 0.222 · 95% CI -4.280 to 4.724The dispersion value is the robust (sandwich) standard error for the estimated GEE coefficient.
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .293 · Time coefficient at t3: 1.537 · 95% CI -1.328 to 4.401The dispersion value is the robust standard error for the estimated GEE coefficient.
SecondaryState Anxiety (STAI-S ) of Surrogates (T0)

The State-Trait Anxiety Inventory-State (STAI-S) assesses current state anxiety. It contains 20 items and yields a total score ranging from 20 to 80; higher scores indicate greater anxiety. Scores are reported as mean and standard deviation for surrogates at baseline.

Time frame:
Baseline (T0)
Reported as:
Mean · scores on a scale
State Anxiety (STAI-S ) of Surrogates (T0)
scores on a scaleExperimental: ACP Tabletop GameControl: ACP Manual
State Anxiety (STAI-S ) of Surrogates (T0)36.03 ± 10.6836.39 ± 11.56
Statistical analysis
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .901 · Experimental group coefficient: -0.353 · 95% CI -5.885 to 5.179The dispersion value is the robust (sandwich) standard error for the estimated GEE coefficient.
SecondaryState Anxiety (STAI-S ) of Surrogates (T1)

The State-Trait Anxiety Inventory-State (STAI-S) assesses current state anxiety. It contains 20 items and yields a total score ranging from 20 to 80; higher scores indicate greater anxiety. Scores are reported as mean and standard deviation for surrogates immediately post-intervention.

Time frame:
immediately post-intervention (T1)
Reported as:
Mean · scores on a scale
State Anxiety (STAI-S ) of Surrogates (T1)
scores on a scaleExperimental: ACP Tabletop GameControl: ACP Manual
State Anxiety (STAI-S ) of Surrogates (T1)33.38 ± 8.6134.45 ± 9.53
Statistical analysis
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .560 · Group×time coefficient at t1: -0.720 · 95% CI -3.138 to 1.698The dispersion value is the robust (sandwich) standard error for the estimated GEE coefficient.
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .033 · Time coefficient at t1: -1.935 · 95% CI -3.710 to -0.161The dispersion value is the robust standard error for the estimated GEE coefficient.
SecondaryState Anxiety (STAI-S ) of Surrogates (T2)

The State-Trait Anxiety Inventory-State (STAI-S) assesses current (state) anxiety. It includes 20 items and yields a total score range of 20 to 80; higher scores indicate higher anxiety. Scores are reported as mean (standard deviation) for surrogates at the specified time point.

Time frame:
2 weeks post-intervention (T2)
Reported as:
Mean · scores on a scale
State Anxiety (STAI-S ) of Surrogates (T2)
scores on a scaleExperimental: ACP Tabletop GameControl: ACP Manual
State Anxiety (STAI-S ) of Surrogates (T2)37.48 ± 11.5735.84 ± 10.60
Statistical analysis
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .325 · Group×time coefficient at t2: 1.997 · 95% CI -1.977 to 5.970The dispersion value is the robust standard error for the estimated GEE coefficient.
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .692 · Time coefficient at t2: -0.548 · 95% CI -3.262 to 2.165The dispersion value is the robust standard error for the estimated GEE coefficient.
PrimaryAbsolute Gap Score on m-LSPQ Total Score at 2 Weeks

The modified Life Support Preferences Questionnaire (m-LSPQ) contains 45 items rated from 1 (absolutely unwanted) to 5 (absolutely wanted). The total score is calculated by summing all 45 item scores and ranges from 45 to 225; higher scores indicate a greater preference for receiving life-sustaining treatments. Patient and surrogate total scores are reported separately. For each patient-surrogate dyad, the absolute gap score is calculated as \|surrogate total score - patient total score\|. The absolute gap score ranges from 0 to 180; smaller values indicate greater patient-surrogate concordance, with 0 indicating complete agreement.

Time frame:
2 weeks post-intervention (T2)
Reported as:
Mean · scores on a scale
Absolute Gap Score on m-LSPQ Total Score at 2 Weeks
scores on a scaleExperimental: ACP Tabletop GameControl: ACP Manual
Patient total m-LSPQ score122.14 ± 45.04108.55 ± 43.06
Surrogate total m-LSPQ score126.93 ± 44.10134.39 ± 47.25
Absolute gap |Surrogate-Patient|49.34 ± 26.3043.03 ± 31.06
Statistical analysis
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .376 · Group×time coefficient at 2 weeks: 6.190 · 95% CI -7.506 to 19.886The dispersion value represents the robust (sandwich) standard error of the GEE coefficient.
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .162 · Time coefficient at 2 weeks: -5.742 · 95% CI -13.797 to 2.313The dispersion value is the robust (sandwich) standard error for the estimated GEE coefficient.
PrimaryAbsolute Gap Score on m-LSPQ Total Score at 6 Weeks

The modified Life Support Preferences Questionnaire (m-LSPQ) contains 45 items rated from 1 (absolutely unwanted) to 5 (absolutely wanted). The total score is calculated by summing all 45 item scores and ranges from 45 to 225; higher scores indicate a greater preference for receiving life-sustaining treatments. Patient and surrogate total scores are reported separately. For each patient-surrogate dyad, the absolute gap score is calculated as \|surrogate total score - patient total score\|. The absolute gap score ranges from 0 to 180; smaller values indicate greater patient-surrogate concordance, with 0 indicating complete agreement.

Time frame:
6 weeks post-intervention (T3)
Reported as:
Mean · scores on a scale
Absolute Gap Score on m-LSPQ Total Score at 6 Weeks
scores on a scaleExperimental: ACP Tabletop GameControl: ACP Manual
Patient total m-LSPQ score117.28 ± 44.17101.86 ± 37.73
Surrogate total m-LSPQ score130.66 ± 48.10129.43 ± 41.77
Absolute gap |Surrogate-Patient|39.17 ± 20.5046.32 ± 28.18
Statistical analysis
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .251 · Group×time coefficient at 6 weeks: -6.312 · 95% CI -17.088 to 4.464The dispersion value represents the robust (sandwich) standard error of the GEE coefficient.
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .362 · Time coefficient at 6 weeks: -3.412 · 95% CI -10.751 to 3.927The dispersion value is the robust (sandwich) standard error for the estimated GEE coefficient.
SecondaryState Anxiety (STAI-S ) of Surrogates (T3)

The State-Trait Anxiety Inventory-State (STAI-S) assesses current (state) anxiety. It includes 20 items and yields a total score range of 20 to 80; higher scores indicate higher anxiety. Scores are reported as mean (standard deviation) for surrogates at the specified time point.

Time frame:
6 weeks post-intervention (T3)
Reported as:
Mean · scores on a scale
State Anxiety (STAI-S ) of Surrogates (T3)
scores on a scaleExperimental: ACP Tabletop GameControl: ACP Manual
State Anxiety (STAI-S ) of Surrogates (T3)37.31 ± 10.9632.82 ± 8.17
Statistical analysis
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .116 · Group×time coefficient at t3: 3.539 · 95% CI -0.869 to 7.946The dispersion value is the robust standard error for the estimated GEE coefficient.
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .097 · Time coefficient at t3: -2.263 · 95% CI -4.935 to 0.410The dispersion value is the robust standard error for the estimated GEE coefficient.
SecondaryAbsolute Gap in Antibiotics Preference (T0)

The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 (absolutely unwanted) to 5 (absolutely wanted). The antibiotics subscale includes 9 items, with total scores ranging from 9 to 45. Higher scores indicate a greater preference for receiving antibiotics. Patient and surrogate subscale scores are reported separately. For each patient-surrogate dyad, the absolute gap score was calculated as \|surrogate score - patient score\|. Gap scores range from 0 to 36; smaller scores indicate greater patient-surrogate concordance, with 0 indicating complete agreement.

Time frame:
Baseline (T0)
Reported as:
Mean · scores on a scale
Absolute Gap in Antibiotics Preference (T0)
scores on a scaleExperimental: ACP Tabletop GameControl: ACP Manual
Patient Antibiotics score28.72 ± 11.5928.42 ± 10.54
Surrogate Antibiotics score32.59 ± 9.1131.13 ± 11.29
Absolute gap |Surrogate-Patient|10.48 ± 6.109.77 ± 6.99
Statistical analysis
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .670 · Experimental group coefficient: 0.709 · 95% CI -2.551 to 3.968
SecondaryAbsolute Gap in Antibiotics Preference (T2)

The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 (absolutely unwanted) to 5 (absolutely wanted). The antibiotics subscale includes 9 items, with total scores ranging from 9 to 45. Higher scores indicate a greater preference for receiving antibiotics. Patient and surrogate subscale scores are reported separately. For each patient-surrogate dyad, the absolute gap score was calculated as \|surrogate score - patient score\|. Gap scores range from 0 to 36; smaller scores indicate greater patient-surrogate concordance, with 0 indicating complete agreement.

Time frame:
2 weeks post-intervention (T2)
Reported as:
Mean · scores on a scale
Absolute Gap in Antibiotics Preference (T2)
scores on a scaleExperimental: ACP Tabletop GameControl: ACP Manual
Patient Antibiotics score30.38 ± 10.4726.74 ± 10.16
Surrogate Antibiotics score30.24 ± 9.9632.71 ± 10.27
Absolute gap |Surrogate-Patient|10.00 ± 8.628.71 ± 7.51
Statistical analysis
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .787 · Group x time coefficient at 2 weeks: 0.582 · 95% CI -3.632 to 4.796Robust (sandwich) standard errors; Wald chi-square test
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · Time coefficient at 2 weeks · p = .400 · Time coefficient at 2 weeks: -1.065 · 95% CI -3.542 to 1.413The dispersion value is the robust standard error for the estimated GEE coefficient.
SecondaryAbsolute Gap in Antibiotics Preference (T3)

The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 = "absolutely unwanted" to 5 = "absolutely wanted." The antibiotics subscale includes 9 items, one for each health scenario. Subscale scores are calculated by summing the 9 item scores, with possible scores ranging from 9 to 45. Higher scores indicate greater preference for receiving antibiotics as a life-sustaining treatment. The absolute gap score for antibiotics preference was calculated as \|Surrogate antibiotics subscale score - Patient antibiotics subscale score\|. Scores range from 0 to 36, with smaller values indicating greater patient-surrogate concordance.

Time frame:
6 weeks post-intervention (T3)
Reported as:
Mean · scores on a scale
Absolute Gap in Antibiotics Preference (T3)
scores on a scaleExperimental: ACP Tabletop GameControl: ACP Manual
Patient Antibiotics score29.38 ± 11.1926.29 ± 9.93
Surrogate Antibiotics score29.55 ± 10.1631.86 ± 10.79
Absolute gap |Surrogate-Patient|6.59 ± 5.8210.07 ± 7.38
Statistical analysis
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .015 · Group x time coefficient at t3: -4.101 · 95% CI -7.416 to -0.785The dispersion value is the robust standard error for the estimated GEE coefficient.
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .864 · Time coefficient at t3: 0.204 · 95% CI -2.136 to 2.544The dispersion value is the robust standard error for the estimated GEE coefficient.
SecondaryAbsolute Gap in Cardiopulmonary Resuscitation (CPR) Preference (T0)

The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 = "absolutely unwanted" to 5 = "absolutely wanted." The cardiopulmonary resuscitation (CPR) subscale includes 9 items, one for each health scenario. Subscale scores are calculated by summing the 9 item scores, with possible scores ranging from 9 to 45. Higher scores indicate greater preference for receiving CPR as a life-sustaining treatment. The absolute gap score was calculated as \|Surrogate CPR subscale score - Patient CPR subscale score\|. Scores range from 0 to 36, with smaller values indicating greater patient-surrogate concordance.

Time frame:
Baseline (T0)
Reported as:
Mean · scores on a scale
Absolute Gap in Cardiopulmonary Resuscitation (CPR) Preference (T0)
scores on a scaleExperimental: ACP Tabletop GameControl: ACP Manual
Patient CPR score17.55 ± 9.0817.81 ± 9.08
Surrogate CPR score23.59 ± 10.1623.52 ± 11.38
Absolute gap |Surrogate-Patient|8.52 ± 5.409.10 ± 7.60
Statistical analysis
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .728 · Experimental group coefficient: -0.580 · 95% CI -3.844 to 2.685The dispersion value is the robust standard error for the estimated GEE coefficient.
SecondaryAbsolute Gap in Cardiopulmonary Resuscitation (CPR) Preference (T2)

The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 = "absolutely unwanted" to 5 = "absolutely wanted." The cardiopulmonary resuscitation (CPR) subscale includes 9 items, one for each health scenario. Subscale scores are calculated by summing the 9 item scores, with possible scores ranging from 9 to 45. Higher scores indicate greater preference for receiving CPR as a life-sustaining treatment. The absolute gap score was calculated as \|Surrogate CPR subscale score - Patient CPR subscale score\|. Scores range from 0 to 36, with smaller values indicating greater patient-surrogate concordance.

Time frame:
2 weeks post-intervention (T2)
Reported as:
Mean · scores on a scale
Absolute Gap in Cardiopulmonary Resuscitation (CPR) Preference (T2)
scores on a scaleExperimental: ACP Tabletop GameControl: ACP Manual
Patient CPR score18.59 ± 9.9617.45 ± 9.24
Surrogate CPR score21.90 ± 10.5323.52 ± 11.51
Absolute gap |Surrogate-Patient|8.72 ± 6.637.61 ± 6.70
Statistical analysis
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .345 · Group x time coefficient at 2 weeks: 1.691 · 95% CI -1.817 to 5.199The dispersion value is the robust standard error for the estimated GEE coefficient.
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .139 · Time coefficient at 2 weeks: -1.484 · 95% CI -3.449 to 0.481The dispersion value is the robust standard error for the estimated GEE coefficient.
SecondaryAbsolute Gap in Cardiopulmonary Resuscitation (CPR) Preference (T3)

The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 = "absolutely unwanted" to 5 = "absolutely wanted." The cardiopulmonary resuscitation (CPR) subscale includes 9 items, one for each health scenario. Subscale scores are calculated by summing the 9 item scores, with possible scores ranging from 9 to 45. Higher scores indicate greater preference for receiving CPR as a life-sustaining treatment. The absolute gap score was calculated as \|Surrogate CPR subscale score - Patient CPR subscale score\|. Scores range from 0 to 36, with smaller values indicating greater patient-surrogate concordance.

Time frame:
6 weeks post-intervention (T3)
Reported as:
Mean · scores on a scale
Absolute Gap in Cardiopulmonary Resuscitation (CPR) Preference (T3)
scores on a scaleExperimental: ACP Tabletop GameControl: ACP Manual
Patient CPR score17.07 ± 8.9617.96 ± 9.51
Surrogate CPR score22.52 ± 10.7224.75 ± 11.69
Absolute gap |Surrogate-Patient|7.17 ± 4.339.61 ± 7.68
Statistical analysis
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .233 · Group x time coefficient at 6 weeks: -1.713 · 95% CI -4.528 to 1.102The dispersion value is the robust standard error for the estimated GEE coefficient.
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .717 · Time coefficient at 6 weeks: 0.368 · 95% CI -1.625 to 2.362The dispersion value is the robust standard error for the estimated GEE coefficient.
SecondaryAbsolute Gap in Surgery Preference (T0)

The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 = "absolutely unwanted" to 5 = "absolutely wanted." The surgery subscale includes 9 items, one for each health scenario. Subscale scores are calculated by summing the 9 item scores, with possible scores ranging from 9 to 45. Higher scores indicate greater preference for receiving surgery as a life-sustaining treatment. The absolute gap score was calculated as \|Surrogate surgery subscale score - Patient surgery subscale score\|. Scores range from 0 to 36, with smaller values indicating greater patient-surrogate concordance.

Time frame:
Baseline (T0)
Reported as:
Mean · scores on a scale
Absolute Gap in Surgery Preference (T0)
scores on a scaleExperimental: ACP Tabletop GameControl: ACP Manual
Patient surgery score22.45 ± 10.6323.35 ± 10.07
Surrogate surgery score27.34 ± 9.7227.48 ± 10.82
Absolute gap |Surrogate-Patient|9.28 ± 3.4710.19 ± 5.46
Statistical analysis
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .427 · Experimental group coefficient: -0.918 · 95% CI -3.180 to 1.345The dispersion value is the robust standard error for the estimated GEE coefficient.
SecondaryAbsolute Gap in Surgery Preference (T2)

The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 = "absolutely unwanted" to 5 = "absolutely wanted." The surgery subscale includes 9 items, one for each health scenario. Subscale scores are calculated by summing the 9 item scores, with possible scores ranging from 9 to 45. Higher scores indicate greater preference for receiving surgery as a life-sustaining treatment. The absolute gap score was calculated as \|Surrogate surgery subscale score - Patient surgery subscale score\|. Scores range from 0 to 36, with smaller values indicating greater patient-surrogate concordance.

Time frame:
2 weeks post-intervention (T2)
Reported as:
Mean · scores on a scale
Absolute Gap in Surgery Preference (T2)
scores on a scaleExperimental: ACP Tabletop GameControl: ACP Manual
Patient Surgery score23.03 ± 10.6922.35 ± 9.87
Surrogate Surgery score25.62 ± 10.1425.65 ± 10.53
Absolute gap |Surrogate-Patient|10.48 ± 6.178.58 ± 6.29
Statistical analysis
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .076 · Group x time coefficient at 2 weeks: 2.820 · 95% CI -0.293 to 5.933Robust (sandwich) standard errors; Wald chi-square test
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .096 · Time coefficient at 2 weeks: -1.613 · 95% CI -3.511 to 0.285The dispersion value is the robust standard error for the estimated GEE coefficient.
SecondaryAbsolute Gap in Surgery Preference (T3)

The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 = "absolutely unwanted" to 5 = "absolutely wanted." The surgery subscale includes 9 items, one for each health scenario. Subscale scores are calculated by summing the 9 item scores, with possible scores ranging from 9 to 45. Higher scores indicate greater preference for receiving surgery as a life-sustaining treatment. The absolute gap score was calculated as \|Surrogate surgery subscale score - Patient surgery subscale score\|. Scores range from 0 to 36, with smaller values indicating greater patient-surrogate concordance.

Time frame:
6 weeks post-intervention (T3)
Reported as:
Mean · scores on a scale
Absolute Gap in Surgery Preference (T3)
scores on a scaleExperimental: ACP Tabletop GameControl: ACP Manual
Patient Surgery score21.14 ± 10.3220.57 ± 9.24
Surrogate Surgery score25.17 ± 10.4925.25 ± 10.16
Absolute gap |Surrogate-Patient|9.66 ± 6.969.21 ± 5.93
Statistical analysis
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .414 · Group x time coefficient at 6 weeks: 1.447 · 95% CI -2.023 to 4.916The dispersion value is the robust standard error for the estimated GEE coefficient.
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .310 · Time coefficient at 6 weeks: -1.067 · 95% CI -3.129 to 0.994The dispersion value is the robust standard error for the estimated GEE coefficient.
SecondaryAbsolute Gap in Nasogastric Tube Feeding (NG) Preference (T0)

The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 = "absolutely unwanted" to 5 = "absolutely wanted." The nasogastric tube feeding subscale includes 9 items, one for each health scenario. Subscale scores are calculated by summing the 9 item scores, with possible scores ranging from 9 to 45. Higher scores indicate greater preference for receiving nasogastric tube feeding as a life-sustaining treatment. The absolute gap score was calculated as \|Surrogate NG tube feeding subscale score - Patient NG tube feeding subscale score\|. Scores range from 0 to 36, with smaller values indicating greater patient-surrogate concordance.

Time frame:
Baseline (T0)
Reported as:
Mean · scores on a scale
Absolute Gap in Nasogastric Tube Feeding (NG) Preference (T0)
scores on a scaleExperimental: ACP Tabletop GameControl: ACP Manual
Patient NG Tube Feeding score17.48 ± 9.5117.48 ± 8.86
Surrogate NG Tube Feeding score24.14 ± 10.3824.06 ± 10.72
Absolute gap |Surrogate-Patient|10.59 ± 7.729.94 ± 6.66
Statistical analysis
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .723 · Experimental group coefficient: 0.651 · 95% CI -2.946 to 4.248The dispersion value is the robust standard error for the estimated GEE coefficient.
SecondaryAbsolute Gap in Nasogastric Tube Feeding (NG) Preference (T2)

The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 = "absolutely unwanted" to 5 = "absolutely wanted." The nasogastric tube feeding subscale includes 9 items, one for each health scenario. Subscale scores are calculated by summing the 9 item scores, with possible scores ranging from 9 to 45. Higher scores indicate greater preference for receiving nasogastric tube feeding as a life-sustaining treatment. The absolute gap score was calculated as \|Surrogate NG tube feeding subscale score - Patient NG tube feeding subscale score\|. Scores range from 0 to 36, with smaller values indicating greater patient-surrogate concordance.

Time frame:
2 weeks post-intervention (T2)
Reported as:
Mean · scores on a scale
Absolute Gap in Nasogastric Tube Feeding (NG) Preference (T2)
scores on a scaleExperimental: ACP Tabletop GameControl: ACP Manual
Patient NG Tube Feeding score18.10 ± 9.8717.97 ± 9.24
Surrogate NG Tube Feeding score23.41 ± 10.8424.32 ± 10.16
Absolute gap |Surrogate-Patient|9.52 ± 8.717.60 ± 6.51
Statistical analysis
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .936 · Group x time coefficient at 2 weeks: 0.157 · 95% CI -3.691 to 4.005The dispersion value is the robust standard error for the estimated GEE coefficient.
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .169 · Time coefficient at 2 weeks: -1.226 · 95% CI -2.973 to 0.521The dispersion value is the robust standard error for the estimated GEE coefficient.
SecondaryAbsolute Gap in Nasogastric Tube Feeding (NG) Preference (T3)

The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 = "absolutely unwanted" to 5 = "absolutely wanted." The nasogastric tube feeding subscale includes 9 items, one for each health scenario. Subscale scores are calculated by summing the 9 item scores, with possible scores ranging from 9 to 45. Higher scores indicate greater preference for receiving nasogastric tube feeding as a life-sustaining treatment. The absolute gap score was calculated as \|Surrogate NG tube feeding subscale score - Patient NG tube feeding subscale score\|. Scores range from 0 to 36, with smaller values indicating greater patient-surrogate concordance.

Time frame:
6 weeks post-intervention (T3)
Reported as:
Mean · scores on a scale
Absolute Gap in Nasogastric Tube Feeding (NG) Preference (T3)
scores on a scaleExperimental: ACP Tabletop GameControl: ACP Manual
Patient NG Tube Feeding score17.21 ± 9.5116.96 ± 8.64
Surrogate NG Tube Feeding score22.76 ± 10.6322.82 ± 10.05
Absolute gap |Surrogate-Patient|8.55 ± 5.907.96 ± 6.32
Statistical analysis
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .943 · Group x time coefficient at 6 weeks: 0.129 · 95% CI -3.424 to 3.683The dispersion value is the robust standard error for the estimated GEE coefficient.
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .027 · Time coefficient at 6 weeks: -2.164 · 95% CI -4.081 to -0.247The dispersion value is the robust standard error for the estimated GEE coefficient.
SecondaryAbsolute Gap in Intravenous Infusion (IV) Preference (T0)

The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 = "absolutely unwanted" to 5 = "absolutely wanted." The intravenous infusion subscale includes 9 items, one for each health scenario. Subscale scores are calculated by summing the 9 item scores, with possible scores ranging from 9 to 45. Higher scores indicate greater preference for receiving intravenous infusion as a life-sustaining treatment. The absolute gap score was calculated as \|Surrogate intravenous infusion subscale score - Patient intravenous infusion subscale score\|. Scores range from 0 to 36, with smaller values indicating greater patient-surrogate concordance.

Time frame:
Baseline (T0)
Reported as:
Mean · scores on a scale
Absolute Gap in Intravenous Infusion (IV) Preference (T0)
scores on a scaleExperimental: ACP Tabletop GameControl: ACP Manual
Patient Intravenous Infusion score25.97 ± 10.5326.06 ± 10.16
Surrogate Intravenous Infusion score28.59 ± 9.2428.65 ± 10.47
Absolute gap |Surrogate-Patient|10.02 ± 6.509.77 ± 6.71
Statistical analysis
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .877 · Experimental group coefficient: 0.260 · 95% CI -3.026 to 3.546The dispersion value is the robust standard error for the estimated GEE coefficient.
SecondaryAbsolute Gap in Intravenous Infusion (IV) Preference (T2)

The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 = "absolutely unwanted" to 5 = "absolutely wanted." The intravenous infusion subscale includes 9 items, one for each health scenario. Subscale scores are calculated by summing the 9 item scores, with possible scores ranging from 9 to 45. Higher scores indicate greater preference for receiving intravenous infusion as a life-sustaining treatment. The absolute gap score was calculated as \|Surrogate intravenous infusion subscale score - Patient intravenous infusion subscale score\|. Scores range from 0 to 36, with smaller values indicating greater patient-surrogate concordance.

Time frame:
2 weeks post-intervention (T2)
Reported as:
Mean · scores on a scale
Absolute Gap in Intravenous Infusion (IV) Preference (T2)
scores on a scaleExperimental: ACP Tabletop GameControl: ACP Manual
Patient Intravenous Infusion score26.90 ± 10.3825.58 ± 9.72
Surrogate Intravenous Infusion sc28.41 ± 9.5128.32 ± 10.63
Absolute gap |Surrogate-Patient|10.62 ± 6.599.42 ± 7.51
Statistical analysis
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .638 · Group x time coefficient at 2 weeks: 0.941 · 95% CI -2.975 to 4.857The dispersion value is the robust standard error for the estimated GEE coefficient.
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .774 · Time coefficient at 2 weeks: -0.355 · 95% CI -2.775 to 2.065The dispersion value is the robust standard error for the estimated GEE coefficient.
SecondaryAbsolute Gap in Intravenous Infusion (IV) Preference (T3)

The modified Life Support Preferences Questionnaire (m-LSPQ) assesses preferences for life-sustaining treatments across nine health scenarios using a 5-point Likert scale, ranging from 1 = "absolutely unwanted" to 5 = "absolutely wanted." The intravenous infusion subscale includes 9 items, one for each health scenario. Subscale scores are calculated by summing the 9 item scores, with possible scores ranging from 9 to 45. Higher scores indicate greater preference for receiving intravenous infusion as a life-sustaining treatment. The absolute gap score was calculated as \|Surrogate intravenous infusion subscale score - Patient intravenous infusion subscale score\|. Scores range from 0 to 36, with smaller values indicating greater patient-surrogate concordance.

Time frame:
6 weeks post-intervention (T3)
Reported as:
Mean · scores on a scale
Absolute Gap in Intravenous Infusion (IV) Preference (T3)
scores on a scaleExperimental: ACP Tabletop GameControl: ACP Manual
Patient Intravenous Infusion score25.97 ± 10.1624.46 ± 9.24
Surrogate Intravenous Infusion score28.48 ± 9.8728.68 ± 10.38
Absolute gap |Surrogate-Patient|7.21 ± 6.139.46 ± 6.99
Statistical analysis
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .250 · Group x time coefficient at 6 weeks: -2.272 · 95% CI -6.141 to 1.597The dispersion value is the robust standard error for the estimated GEE coefficient.
  • Experimental: ACP Tabletop Game vs Control: ACP Manual · GEE with AR(1) structure · p = .659 · Time coefficient at 6 weeks: -0.555 · 95% CI -3.025 to 1.914The dispersion value is the robust standard error for the estimated GEE coefficient.

Adverse events

Collected over From enrollment (baseline assessment) through 6 weeks post-intervention follow-up.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ACP Tabletop Game0/29 (0%)0/29 (0%)0/29 (0%)
ACP Manual1/31 (3.2%)0/31 (0%)0/31 (0%)

Baseline characteristics

Baseline characteristics are reported for individual participants (patients and surrogates). Randomization occurred at the dyad level. The 4 participants with unavailable baseline data (2 dyads in the experimental arm) had completed consent and randomization but withdrew before completing baseline questionnaires; their data were therefore excluded from baseline analyses but are included in the participant flow. Baseline N = 58 (experimental) vs 62 (control), total 120.

Age, Continuous
Age, Continuous(years)Experimental: ACP Tabletop GameControl:ACP ManualTotal
Age (Patients)68.6 ± 5.9669.5 ± 6.9869.1 ± 6.46
Age (Surrogates)57.8 ± 14.3457.6 ± 11.3657.7 ± 12.78
Sex: Female, Male
Sex: Female, Male(Participants)Experimental: ACP Tabletop GameControl:ACP ManualTotal
sex (Patients) — Female171431
sex (Patients) — Male121729
sex (Surrogates) — Female192039
sex (Surrogates) — Male101121
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Experimental: ACP Tabletop GameControl:ACP ManualTotal
Count of participants——0
Education
Education(Participants)Experimental: ACP Tabletop GameControl:ACP ManualTotal
Elementary school and below(Patients)6915
High school(Patients)13922
College and above(Patients)101323
Elementary school and below (Surrogates)224
High school (Surrogates)9918
College and above (Surrogates)182038
Charlson Comorbidity Index (CCI)
Charlson Comorbidity Index (CCI)(index)Experimental: ACP Tabletop GameControl:ACP ManualTotal
patient (CCI)Comorbidity index8.8 ± 1.537.9 ± 1.908.3 ± 1.77
Charlson Comorbidity Index (CCI), surrogates2.1 ± 2.551.4 ± 1.141.7 ± 1.97
Cancer stage(patients)
Cancer stage(patients)(Participants)Experimental: ACP Tabletop GameControl:ACP ManualTotal
stage I-III178
stage IV282452
Relationship to patient(surrogates)
Relationship to patient(surrogates)(Participants)Experimental: ACP Tabletop GameControl:ACP ManualTotal
Spouse151631
Adult child111324
Other325
08

Study locations

1 site
  • National Taiwan University Hospital
    Taipei, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Apr 2025, 7 months.

Results were first posted in Oct 2026, 1 year 6 months after primary completion.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's 7 months is below that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Jul 2025 → Apr 2025 and completion Sep 2025 → Apr 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2024
First posted
Sep 27, 2024
StartActual
Sep 25, 2024
Primary completionActual
Apr 30, 2025was Jul 2025
CompletionActual
Apr 30, 2025was Sep 2025
Results first posted
Oct 30, 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 30, 2026
Results
Results posted
posted Oct 30, 2026
Start date
Sep 22, 2024→Sep 25, 2024
Oct 30, 2026
Primary completion
Jul 12, 2025→Apr 30, 2025 (actual)
Oct 30, 2026
Study completion
Sep 30, 2025→Apr 30, 2025 (actual)
Oct 30, 2026
Enrollment
120 (estimated)→124 (actual)
Oct 30, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • Edited3.3. The potential agent issurrogate was designated by the elderly personolder adult with lung cancer who may be a family memberas the person who may make medical decisions in the future. The potential agentsurrogate must be at least 18 years old.
Oct 30, 2026
Primary outcomes
3 added, 1 removed
What changed in the outcomes
  • AddedAbsolute Gap Score on m-LSPQ Total Score BaselineTime frame: Baseline (T0)
  • AddedAbsolute Gap Score on m-LSPQ Total Score at 2 WeeksTime frame: 2 weeks post-intervention (T2)
  • AddedAbsolute Gap Score on m-LSPQ Total Score at 6 WeeksTime frame: 6 weeks post-intervention (T3)
  • RemovedConsistency in subsistence disposal preferences between the elderly and potential agentsTime frame: Outcome Measure Total (3 Time Points): First time: before intervention .Second time: 2 weeks after intervention . Last time: 6 weeks after intervention
Oct 30, 2026
Documents
Secondary outcomes
23 added, 1 removed
What changed in the outcomes
  • AddedState Anxiety (STAI-S) of Patients (T0)Time frame: Baseline (T0)
  • AddedState Anxiety (STAI-S) of Patients (T1)Time frame: Immediately post-intervention (T1)
  • AddedState Anxiety (STAI-S) of Patients (T2)Time frame: 2 weeks post-intervention (T2)
  • AddedState Anxiety (STAI-S) of Patients (T3)Time frame: 6 weeks post-intervention (T3)
  • AddedState Anxiety (STAI-S ) of Surrogates (T0)Time frame: Baseline (T0)
  • AddedState Anxiety (STAI-S ) of Surrogates (T1)Time frame: immediately post-intervention (T1)
  • AddedState Anxiety (STAI-S ) of Surrogates (T2)Time frame: 2 weeks post-intervention (T2)
  • AddedState Anxiety (STAI-S ) of Surrogates (T3)Time frame: 6 weeks post-intervention (T3)
  • AddedAbsolute Gap in Antibiotics Preference (T0)Time frame: Baseline (T0)
  • AddedAbsolute Gap in Antibiotics Preference (T2)Time frame: 2 weeks post-intervention (T2)
  • AddedAbsolute Gap in Antibiotics Preference (T3)Time frame: 6 weeks post-intervention (T3)
  • AddedAbsolute Gap in Cardiopulmonary Resuscitation (CPR) Preference (T0)Time frame: Baseline (T0)
  • AddedAbsolute Gap in Cardiopulmonary Resuscitation (CPR) Preference (T2)Time frame: 2 weeks post-intervention (T2)
  • AddedAbsolute Gap in Cardiopulmonary Resuscitation (CPR) Preference (T3)Time frame: 6 weeks post-intervention (T3)
  • AddedAbsolute Gap in Surgery Preference (T0)Time frame: Baseline (T0)
  • AddedAbsolute Gap in Surgery Preference (T2)Time frame: 2 weeks post-intervention (T2)
  • AddedAbsolute Gap in Surgery Preference (T3)Time frame: 6 weeks post-intervention (T3)
  • AddedAbsolute Gap in Nasogastric Tube Feeding (NG) Preference (T0)Time frame: Baseline (T0)
  • AddedAbsolute Gap in Nasogastric Tube Feeding (NG) Preference (T2)Time frame: 2 weeks post-intervention (T2)
  • AddedAbsolute Gap in Nasogastric Tube Feeding (NG) Preference (T3)Time frame: 6 weeks post-intervention (T3)
  • AddedAbsolute Gap in Intravenous Infusion (IV) Preference (T0)Time frame: Baseline (T0)
  • AddedAbsolute Gap in Intravenous Infusion (IV) Preference (T2)Time frame: 2 weeks post-intervention (T2)
  • AddedAbsolute Gap in Intravenous Infusion (IV) Preference (T3)Time frame: 6 weeks post-intervention (T3)
  • RemovedSTAITime frame: Outcome Measure Total (4 Time Points): First time: Before intervention. Second time: After intervention. Third time: 2 weeks after intervention .Last time: 6 weeks after intervention
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Active, not recruiting→Completed
    Results posted
    Start date Sep 22, 2024→Sep 25, 2024
    Primary completion Jul 12, 2025→Apr 30, 2025 (now actual)
    Study completion Sep 30, 2025→Apr 30, 2025 (now actual)
    Enrollment 120 (estimated)→124 (actual)
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • Edited3.3. The potential agent issurrogate was designated by the elderly personolder adult with lung cancer who may be a family memberas the person who may make medical decisions in the future. The potential agentsurrogate must be at least 18 years old.
    Primary outcomes 3 added, 1 removed
    What changed in the outcomes
    • AddedAbsolute Gap Score on m-LSPQ Total Score BaselineTime frame: Baseline (T0)
    • AddedAbsolute Gap Score on m-LSPQ Total Score at 2 WeeksTime frame: 2 weeks post-intervention (T2)
    • AddedAbsolute Gap Score on m-LSPQ Total Score at 6 WeeksTime frame: 6 weeks post-intervention (T3)
    • RemovedConsistency in subsistence disposal preferences between the elderly and potential agentsTime frame: Outcome Measure Total (3 Time Points): First time: before intervention .Second time: 2 weeks after intervention . Last time: 6 weeks after intervention
    Secondary outcomes 23 added, 1 removed
    What changed in the outcomes
    • AddedState Anxiety (STAI-S) of Patients (T0)Time frame: Baseline (T0)
    • AddedState Anxiety (STAI-S) of Patients (T1)Time frame: Immediately post-intervention (T1)
    • AddedState Anxiety (STAI-S) of Patients (T2)Time frame: 2 weeks post-intervention (T2)
    • AddedState Anxiety (STAI-S) of Patients (T3)Time frame: 6 weeks post-intervention (T3)
    • AddedState Anxiety (STAI-S ) of Surrogates (T0)Time frame: Baseline (T0)
    • AddedState Anxiety (STAI-S ) of Surrogates (T1)Time frame: immediately post-intervention (T1)
    • AddedState Anxiety (STAI-S ) of Surrogates (T2)Time frame: 2 weeks post-intervention (T2)
    • AddedState Anxiety (STAI-S ) of Surrogates (T3)Time frame: 6 weeks post-intervention (T3)
    • AddedAbsolute Gap in Antibiotics Preference (T0)Time frame: Baseline (T0)
    • AddedAbsolute Gap in Antibiotics Preference (T2)Time frame: 2 weeks post-intervention (T2)
    • AddedAbsolute Gap in Antibiotics Preference (T3)Time frame: 6 weeks post-intervention (T3)
    • AddedAbsolute Gap in Cardiopulmonary Resuscitation (CPR) Preference (T0)Time frame: Baseline (T0)
    • AddedAbsolute Gap in Cardiopulmonary Resuscitation (CPR) Preference (T2)Time frame: 2 weeks post-intervention (T2)
    • AddedAbsolute Gap in Cardiopulmonary Resuscitation (CPR) Preference (T3)Time frame: 6 weeks post-intervention (T3)
    • AddedAbsolute Gap in Surgery Preference (T0)Time frame: Baseline (T0)
    • AddedAbsolute Gap in Surgery Preference (T2)Time frame: 2 weeks post-intervention (T2)
    • AddedAbsolute Gap in Surgery Preference (T3)Time frame: 6 weeks post-intervention (T3)
    • AddedAbsolute Gap in Nasogastric Tube Feeding (NG) Preference (T0)Time frame: Baseline (T0)
    • AddedAbsolute Gap in Nasogastric Tube Feeding (NG) Preference (T2)Time frame: 2 weeks post-intervention (T2)
    • AddedAbsolute Gap in Nasogastric Tube Feeding (NG) Preference (T3)Time frame: 6 weeks post-intervention (T3)
    • AddedAbsolute Gap in Intravenous Infusion (IV) Preference (T0)Time frame: Baseline (T0)
    • AddedAbsolute Gap in Intravenous Infusion (IV) Preference (T2)Time frame: 2 weeks post-intervention (T2)
    • AddedAbsolute Gap in Intravenous Infusion (IV) Preference (T3)Time frame: 6 weeks post-intervention (T3)
    • RemovedSTAITime frame: Outcome Measure Total (4 Time Points): First time: Before intervention. Second time: After intervention. Third time: 2 weeks after intervention .Last time: 6 weeks after intervention
    + 4 other changes: index terms, verification date, description and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06616909
Responsible party
Sponsor
First posted
Sep 27, 2024
Start date
Sep 25, 2024
Primary completion
Apr 30, 2025
Completion
Apr 30, 2025
Results posted
Oct 30, 2026
Last update
Oct 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion